Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides metabolic energy via glycolysis and the Krebs cycle, replenishing extracellular fluid glucose. Sodium and chloride are major extracellular electrolytes that maintain osmotic pressure and fluid balance; chloride serves as a counterion for acid-base regulation. Potassium is the primary intracellular cation essential for membrane potential, nerve impulse transmission, and muscle contraction. The solution provides water, electrolytes, and calories to correct fluid, electrolyte, and caloric deficits.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Fluid and electrolyte replacement in patients with mild to moderate hyponatremia and hypokalemia,Maintenance of hydration and provision of calories to prevent ketosis in patients unable to take oral fluids,Replacement of water, sodium, chloride, and potassium losses in isotonic or hypotonic dehydration
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion; dose depends on fluid, electrolyte, and caloric needs. Typical adult dose: 1000-2000 m L/day, administered at 100-200 m L/hour. Potassium replacement: 20 m Eq/L of solution, infused at a rate not exceeding 10 m Eq/hour, with a maximum daily dose of 200 m Eq.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Glucose: 1.5-2 h; potassium: 8-12 h; sodium: 12-24 h; clinical context: half-life affected by renal function and total body stores.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Dextrose is metabolized in all tissues via glycolysis to pyruvate, then enters the Krebs cycle; excess is stored as glycogen or converted to fat. Sodium and chloride are not metabolized but excreted renally under hormonal control (aldosterone, ADH). Potassium is actively transported into cells via Na+/K+-ATPase and excreted primarily by the kidneys.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal: glucose <0.5% excreted unchanged; sodium and potassium >90% reabsorbed; chloride follows sodium. Biliary/fecal: negligible.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Glucose: none; sodium and chloride: none; potassium: none.
Low protein binding; 0–11% bound, primarily to albumin.
Glucose: 0.2-0.3 L/kg (extracellular fluid); sodium: 0.15-0.2 L/kg (plasma and interstitial); potassium: 0.4-0.6 L/kg (total body water).
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
IV: 100% for all components; oral: not applicable (IV only).
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
GFR >50 m L/min: No adjustment. GFR 10-50 m L/min: Reduce infusion rate; monitor serum potassium; avoid if hyperkalemia risk. GFR <10 m L/min: Use with extreme caution; consider alternative potassium source; monitor ECG and serum potassium frequently.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
Child-Pugh Class A: No specific adjustment. Class B: Reduced doses due to potential for fluid retention; monitor serum potassium. Class C: Avoid due to increased risk of hyperkalemia and fluid overload.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Intravenous infusion; dose based on weight and clinical status. Typical: 5-10 m L/kg/day of the solution, adjusted for electrolyte needs. Infusion rate: Do not exceed 0.5 m Eq/kg/hour of potassium. Maximum potassium concentration: 40 m Eq/L. Monitor serum electrolytes closely.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Elderly patients may have decreased renal function; initiate at lower infusion rates (e.g., 50-100 m L/hour) and titrate based on serum potassium. Monitor renal function and electrolytes frequently; avoid overhydration.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Monitor serum electrolytes, fluid balance, and renal function. Use with caution in patients with cardiac or renal impairment, hyperkalemia, hyponatremia, or conditions predisposing to fluid overload (heart failure, pulmonary edema). Rapid infusion may cause hyperglycemia, hyperosmolarity, or osmotic diuresis. Potassium-containing solutions must be administered with care in patients on potassium-sparing diuretics, ACE inhibitors, or with impaired renal function. Do not administer unless solution is clear and container undamaged.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperkalemia, severe renal insufficiency (oliguria or anuria), hypernatremia, fluid overload states (e.g., pulmonary edema, decompensated heart failure), severe hypokalemia (until corrected), and known hypersensitivity to any component.
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No specific food interactions. However, potassium intake from diet should be considered in patients with renal impairment or hyperkalemia. Avoid salt substitutes containing potassium without medical advice.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
FDA Pregnancy Category C. Dextrose and electrolytes are generally considered low risk when used at physiological doses. Potassium chloride is essential for fetal development; hyperkalemia or hypokalemia may cause fetal arrhythmias. No known teratogenicity in first trimester. Second and third trimester: risk of electrolyte imbalances affecting fetal homeostasis. Use only if clearly needed.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Compatible with breastfeeding. Dextrose and electrolytes are normal constituents of human milk. Potassium levels in milk are tightly regulated; M/P ratio not applicable. No adverse effects reported.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy increases plasma volume and GFR, which may alter electrolyte requirements. Dose adjustments are generally not needed for maintenance; however, consider increased fluid and electrolyte needs. Monitor potassium levels closely as total body potassium changes. Adjust infusion rate based on maternal electrolyte status.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Do not administer if solution is discolored or contains precipitate. Inspect for leaks and ensure container is intact. Use strict aseptic technique when spiking bag. Monitor serum potassium levels closely in renal impairment. Rate of infusion should not exceed 0.5-1 m Eq/kg/hour potassium. Do not add other medications unless compatibility verified. For peripheral administration, ensure proper vein selection to avoid phlebitis.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Report any pain, redness, or swelling at the IV site immediately.,Inform your doctor if you have kidney problems, heart disease, or are on a low-potassium diet.,This solution contains dextrose; if you are diabetic, your blood sugar will be monitored.,Do not adjust the IV drip rate yourself.,Tell your doctor if you experience muscle weakness, tingling, or irregular heartbeat.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) is a Electrolyte that works by Dextrose is a monosaccharide that provides metabolic energy via glycolysis and the Krebs cycle, replenishing extracellular fluid glucose. Sodium and chloride are major extracellular electrolytes that maintain osmotic pressure and fluid balance; chloride serves as a counterion for acid-base regulation. Potassium is the primary intracellular cation essential for membrane potential, nerve impulse transmission, and muscle contraction. The solution provides water, electrolytes, and calories to correct fluid, electrolyte, and caloric deficits.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) is: Intravenous infusion; dose depends on fluid, electrolyte, and caloric needs. Typical adult dose: 1000-2000 m L/day, administered at 100-200 m L/hour. Potassium replacement: 20 m Eq/L of solution, infused at a rate not exceeding 10 m Eq/hour, with a maximum daily dose of 200 m Eq.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K) is classified as Category A/B. FDA Pregnancy Category C. Dextrose and electrolytes are generally considered low risk when used at physiological doses. Potassium chloride is essential for fetal development; hyper. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.